Nerve agent hydrolysis activity designed into a human drug metabolism enzyme

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Hemmert, Andrew C ^a   Otto, Tamara C ^b   Chica, Roberto A ^c,f   Wierdl, Monika ^d   Edwards, Jonathan S ^a   Lewis, Steven L ^a   Edwards, Carol C ^d   Tsurkan, Lyudmila ^d   Cadieux, C Linn ^b   Kasten, Shane A ^b   Cashman, John R ^e   Mayo, Stephen L ^c   Potter, Philip M ^d   Cerasoli, Douglas M ^b   Redinbo, Matthew R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CYCLOSARIN; DRUG METABOLIZING ENZYME; GLUTAMIC ACID; HISTIDINE; SARIN; SOMAN; UNCLASSIFIED DRUG; CES1 PROTEIN, HUMAN; CHEMICAL WARFARE AGENT; ORGANOPHOSPHORUS COMPOUND;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; HYDROLYSIS; MOLECULAR MODEL; PROTEIN VARIANT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEIN CONFORMATION;

CARBOXYLIC ESTER HYDROLASES; CATALYTIC DOMAIN; CHEMICAL WARFARE AGENTS; HUMANS; HYDROLYSIS; MODELS, MOLECULAR; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PROTEIN CONFORMATION;

EID: 79952789846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017441     Document Type: Article

References (30)

1. Dixon M, Webb EC, (1979) Enzymes. 3rd ed New York Academic Press.
2. Newmark J, (2007) Nerve agents. Neurologist 13: 20-32.
3. Ohbu S, Yamashina A, (1997) Sarin poisoning on Tokyo subway. Southern Medical Journal 90: 587-693.
4. Gunnell D, Eddleston M, Phillips MR, Konradsen F, (2007) The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health 7: 357.
5. Jett DA, Finding new cures for neurological disorders: a possible fringe benefit of biodefense research? Sci Transl Med 2: 23ps12.
6. Redinbo MR, Potter PM, (2005) Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today 10: 313-325.
7. Fleming CD, Edwards CC, Kirby SD, Maxwell DM, Potter PM, et al. (2007) Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. Biochemistry 46: 5063-5071.
8. Hemmert AC, Otto TC, Wierdl M, Edwards CC, Fleming CD, et al. (2010) Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin. Mol Pharmacol 77: 508-516.
9. Marcel V, Estrada-Mondaca S, Magne F, Stojan J, Klaebe A, et al. (2000) Exploration of the Drosophila acetylcholinesterase substrate activation site using a reversible inhibitor (Triton X-100) and mutated enzymes. J Biol Chem 275: 11603-11609.
10. Millard CB, Lockridge O, Broomfield CA, (1998) Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 37: 237-247.
11. Wierdl M, Tsurkan L, Hyatt JL, Edwards CC, Hatfield MJ, et al. (2008) An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 15: 183-192.
12. Casida JE, Quistad GB, (2005) Serine hydrolase targets of organophosphorus toxicants. Chem Biol Interact 157-158: 277-283.
13. Gilley C, MacDonald M, Nachon F, Schopfer LM, Zhang J, et al. (2009) Nerve agent analogues that produce authentic soman, sarin, tabun, and cyclohexyl methylphosphonate-modified human butyrylcholinesterase. Chem Res Toxicol 22: 1680-1688.
14. Lenz DE, Broomfield CA, Yeung D, Masson P, Maxwell DM, et al. (2008) Nerve Agent Bioscavengers: Progress in Development of a New Mode of Protection against Organophosphorus Exposure. In: Romano JA, Lukey BJ, Salem H, editors. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 2nd ed Boca Raton, FL CRC Press pp. 175-202.
15. Qian N, Kovach IM, (1993) Key active site residues in the inhibition of acetylcholinesterases by soman. FEBS Lett 336: 263-266.
16. Millard CB, Lockridge O, Broomfield CA, (1995) Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry 34: 15925-15933.
17. Kuca K, Jun D, Bajgar J, (2007) Currently used cholinesterase reactivators against nerve agent intoxication: comparison of their effectivity in vitro. Drug Chem Toxicol 30: 31-40.
18. Lockridge O, Blong RM, Masson P, Froment MT, Millard CB, et al. (1997) A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry 36: 786-795.
19. Vocadlo DJ, Davies GJ, Laine R, Withers SG, (2001) Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate. Nature 412: 835-838.
20. Denu JM, Dixon JE, (1998) Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr Opin Chem Biol 2: 633-641.
21. Wolfenden R, (2006) Degrees of difficulty of water-consuming reactions in the absence of enzymes. Chem Rev 106: 3379-3396.
22. Wadkins RM, Morton CL, Weeks JK, Oliver L, Wierdl M, et al. (2001) Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol 60: 355-362.
23. Elcock AH, Gabdoulline RR, Wade RC, McCammon JA, (1999) Computer simulation of protein-protein association kinetics: acetylcholinesterase-fasciculin. J Mol Biol 291: 149-162.
24. Morton CL, Potter PM, (2000) Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression. Application to a rabbit liver carboxylesterase. Mol Biotechnol 16: 193-202.
25. Hovanec JW, Broomfield CA, Steinberg GM, Lanks KW, Lieske CN, (1977) Spontaneous reactivation of acetylcholinesterase following organophosphate inhibition. I. An analysis of anomalous reactivation kinetics. Biochim Biophys Acta 483: 312-319.
26. Aurbek N, Thiermann H, Szinicz L, Eyer P, Worek F, (2006) Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology 224: 91-99.
27. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, et al. (2009) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21.
28. Dunbrack RL Jr, Cohen FE, (1997) Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci 6: 1661-1681.
29. Mayo S, Olafson B, Goddard W, (1990) DREIDING: A Generic Force Field for Molecular Simulations. J Phys Chem 94: 8897-8909.
30. Shortle D, (2003) Propensities, probabilities, and the Boltzmann hypothesis. Protein Sci 12: 1298-1302.